Pregnancy mRNA Vaccination Cuts COVID-19 Hospitalisation by Half Across Europe
A four-country target trial emulation gives pharmacists pregnancy-specific, brand-inclusive estimates of mRNA vaccine and booster effectiveness during Delta and Omicron circulation.
📅 Journal publication: Oct 16, 2026·Last updated: Nov 18, 2026
COVID-19 vaccines lower hospitalisation risk for pregnant women.
Understanding COVID-19 vaccine effectiveness in pregnant women aids in balancing maternal and fetal health during pandemics. Primary vaccination showed 55.6% effectiveness against hospitalisation, while booster provided 34.1% effectiveness. The study supports recommending mRNA COVID-19 vaccination during pregnancy for reducing hospitalisation risk. Data is more variable for infection prevention. mRNA COVID-19 vaccination during pregnancy reduces hospitalisation risk, with variable infection protection.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Mercadé-Besora N, Raventós B, Trinh NT, Li H, Hayati S, Giuliodori A, Burkard T, Burn E, Català M, Prieto-Alhambra D, Morales DR, Nyberg F, Marie Egeland Nordeng H, Duarte-Salles T
Citation:Mercadé-Besora N, Raventós B, Trinh NT, et al. Target trial emulation of effectiveness of COVID-19 mRNA vaccination during pregnancy in four European countries. Nature communications. 2026;17(1). doi:10.1038/s41467-026-78469-x